Literature DB >> 7525393

Immunization with the larger isoform of mouse glutamic acid decarboxylase (GAD67) prevents autoimmune diabetes in NOD mice.

J F Elliott1, H Y Qin, S Bhatti, D K Smith, R K Singh, T Dillon, J Lauzon, B Singh.   

Abstract

The 65-kDa isoform of glutamic acid decarboxylase (GAD65) has been implicated in autoimmune diabetes in NOD mice, but the role of the 67-kDa GAD isoform (GAD67) is less clear. We found that immunization of 4-week-old NOD mice with purified recombinant mouse GAD67 prevented or significantly delayed the onset of diabetes. To further explore this phenomenon, we characterized anti-GAD67 immune responses in naive and GAD-immunized NOD mice. Anti-GAD67 antibodies titers were relatively low in naive mice at all ages, but a single immunization with GAD67 at 4 weeks induced high titers of anti-GAD antibodies by 6 weeks of age. In both 4-week-old and diabetic NOD mice, there were significant endogenous T-cell proliferative responses against purified recombinant mouse GAD67. These T-cell proliferative responses were blocked by anti-I-ANOD and anti-CD4 antibodies. To characterize the anti-GAD T-cell responses in the NOD mice, we established T-cell lines and T-cell clones which recognized GAD67, and we used recombinant subfragments of GAD to localize the predominant T-cell epitopes in GAD67. T-cells from naive NOD mice proliferated in response to all GAD subfragments, whereas T-cells from diabetic mice responded primarily to the COOH-terminal 83 amino acids of GAD67. These results suggest that GAD67 is an autoantigen in IDDM and immunization of prediabetic NOD mice with GAD67 can prevent the onset of diabetes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525393     DOI: 10.2337/diab.43.12.1494

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  28 in total

Review 1.  Immunotherapy of immune-mediated diabetes. Present and future.

Authors:  N Maclaren
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 2.  Immune mechanisms that regulate susceptibility to autoimmune type I diabetes.

Authors:  B Singh; T L Delovitch
Journal:  Clin Rev Allergy Immunol       Date:  2000-12       Impact factor: 8.667

Review 3.  The non obese diabetic (NOD) mouse: a unique model for understanding the interaction between genetics and T cell responses.

Authors:  William M Ridgway
Journal:  Rev Endocr Metab Disord       Date:  2003-09       Impact factor: 6.514

Review 4.  T-cell autoantigens in the non-obese diabetic mouse model of autoimmune diabetes.

Authors:  Jeffrey Babad; Ari Geliebter; Teresa P DiLorenzo
Journal:  Immunology       Date:  2010-10-13       Impact factor: 7.397

5.  An update on the use of NOD mice to study autoimmune (Type 1) diabetes.

Authors:  Rodolfo José Chaparro; Teresa P Dilorenzo
Journal:  Expert Rev Clin Immunol       Date:  2010-11       Impact factor: 4.473

6.  Anti-GAD monoclonal antibody delays the onset of diabetes mellitus in NOD mice.

Authors:  V Menard; H Jacobs; H S Jun; J W Yoon; S W Kim
Journal:  Pharm Res       Date:  1999-07       Impact factor: 4.200

Review 7.  Viruses, cytokines, antigens, and autoimmunity.

Authors:  R Gianani; N Sarvetnick
Journal:  Proc Natl Acad Sci U S A       Date:  1996-03-19       Impact factor: 11.205

Review 8.  Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies?

Authors:  Lucienne Chatenoud
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

9.  Induction of insulitis by glutamic acid decarboxylase peptide-specific and HLA-DQ8-restricted CD4(+) T cells from human DQ transgenic mice.

Authors:  L Wen; F S Wong; L Burkly; M Altieri; C Mamalaki; D Kioussis; R A Flavell; R S Sherwin
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

10.  Transgenically induced GAD tolerance curtails the development of early beta-cell autoreactivities but causes the subsequent development of supernormal autoreactivities to other beta-cell antigens.

Authors:  Jide Tian; Hoa Dang; Harald von Boehmer; Elmar Jaeckel; Daniel L Kaufman
Journal:  Diabetes       Date:  2009-09-09       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.